

PROVIDER QUICK POINTS

PROVIDER INFORMATION



August 14, 2019

Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Hemophilia VIII and IX Extended Half-Life Products

Effective October 1, 2019, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) will require PA with QL for Hemophilia VIII and IX Extended Half-Life Products under the pharmacy benefit plan.

The intent of the Hemophilia VIII and IX Extended Half-Life Products PA with QL program is to promote appropriate selection of patients for treatment according to product labeling and/or clinical guidelines and/or clinical studies.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring they receive appropriate, quality care while also managing overall costs. The PA process ensures that the health service or drug being proposed is medically necessary, and reflective of evidence-based medicine and industry standards, prior to treatment. This process helps us manage the cost and quality of care appropriately for our members.

Target Agent(s)	Quantity Limit (per day)
Alprolix [®] [Coagulation Factor IX (recombinant), Fc Fusion protein] Idelvion [®] [Coagulation Factor IX (recombinant), Albumin Fusion Protein (RIX-FP)] Rebinyn [®] [Coagulation Factor IX (Recombinant), GlycoPEGylated] Adynovate [®] [Antihemophilic Factor (recombinant) PEGylated] Afstyla [®] [Antihemophilic Factor (recombinant), Single Chain] Eloctate [®] [Antihemophilic Factor (recombinant), Fc Fusion Protein] Jivi [®] [Antihemophilic Factor (recombinant), PEGylated-aucl]	Dependent on patient weight and number of doses

Products Impacted

This PA program applies to commercial lines of business.

New PA criteria will be posted by September 1, 2019 and may be accessed using the Blue Cross provider link.

- Access **providers.bluecrossmn.com**
- Under Tools and Resources, select Medical policy, then acknowledge the Acceptance statement
- Select View All Active Policies
- Select Pharmacy Utilization Management Programs

CoverMyMeds prior authorization request service

Prescribers can submit ePA drug requests for Blue Cross subscribers who have pharmacy benefits through Blue Cross by either submitting a request through CoverMyMeds's (CMM) free web portal or by sending an electronic NCPDP file to Prime through an integrated Electronic Medical Record (EMR) system during the e-prescribing process.

QP72-19

Distribution: Available online at: <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Continued

- To access CMM, go to www.covernymeds.com
- The first time you use the portal to submit a PA, you will need to create a CMM account.
- For help using the CMM site select Support (top of the web page) to view FAQs, CMM physician training webinar offerings, and support options to help you get started.

Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.